Evidence
Life Sci. 2024 Jan 17:122431. doi: 10.1016/j.lfs.2024.122431. Online ahead of print.
ABSTRACT
Liver disease has become one of the main causes of health issue worldwide. Sirtuin (Sirt) 2 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, and is expressed in multiple organs including liver, which plays important and complex roles by interacting with various substrates. Physiologically, Sirt2 can improve metabolic homeostasis. Pathologically, Sirt2 can alleviate inflammation, endoplasmic reticulum (ER) stress, promote liver regeneration, maintain iron homeostasis, aggravate fibrogenesis and regulate oxidative stress in liver. In liver diseases, Sirt2 can mitigate fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), but aggravate hepatitis B (HBV) and liver ischemia-reperfusion injury (LIRI). The role of Sirt2 in liver cancer and aging-related liver diseases, however, has not been fully elucidated. In this review, these biological processes regulated by Sirt2 in liver are summarized, which aims to update the function of Sirt2 in liver and to explore the potential role of Sirt2 as a therapeutic target for liver diseases.
PMID:38242495 | DOI:10.1016/j.lfs.2024.122431
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 90 Days
VR Related Evidence Matrix
- Emerging roles of RNA-binding proteins in fatty liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- The gut-liver axis in fatty liver disease: role played by natural products
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Inflammatory liver diseases and susceptibility to sepsis
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Occult liver disease: a multinational perspective
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Spatial genomics: mapping human steatotic liver disease
- Fucoidan from Apostichopus japonicus ameliorates alcoholic liver disease by regulating gut-liver axis homeostasis
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Interleukins in liver disease treatment
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- NcRNA Regulated Pyroptosis in Liver Diseases and Traditional Chinese Medicine Intervention: A Narrative Review
- Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease
- Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Efficacy of Jiuzao polysaccharides in ameliorating alcoholic fatty liver disease and modulating gut microbiota
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- COVID-19 in Individuals with Chronic Liver Diseases
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
Evidence Blueprint
The role of Sirtuin 2 in liver – An extensive and complex biological process
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 365 Days
VR Related Evidence Matrix
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT/NAD+/SIRT1 axis
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Emerging roles of RNA-binding proteins in fatty liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Hormone action and liver disease, a complex interplay
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Nicotinamide N-methyltransferase and liver diseases
- Liver sinusoidal endothelial transcription factors in metabolic homeostasis and disease
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease
- Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease
- The gut-liver axis in fatty liver disease: role played by natural products
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Inflammatory liver diseases and susceptibility to sepsis
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Fatty liver disease's renaming impacts on drug clinical trials
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
- Corrected and republished from: Metabolic associated liver disease
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- The double roles of T cell-mediated immune response in the progression of MASLD
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Phospholipid metabolism in the liver - Implications for phosphatidylserine in non-alcoholic fatty liver disease
- Alcoholic liver disease - 2023
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Dissecting the potential role of ferroptosis in liver diseases: an updated review
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Pharmacology of bioactive compounds from plant extracts for improving non-alcoholic fatty liver disease through endoplasmic reticulum stress modulation: A comprehensive review